Disease · MONDO_0006608
Targets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 12 of 12
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Tyrosine-protein kinase JAK3 | 1 | Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| PDE4A | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | Phosphodiesterase 4 | 1 | Phosphodiesterase 4 inhibitor | Phase 3 | https://conductscience.org/library/genes/5144 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 1 | Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 1 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor antagonist | Phase 2 | https://conductscience.org/library/genes/7442 | Drugs and targets |
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | 1 | Tyrosine-protein kinase TYK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006608/targets